Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 13/20 | 0.49 |
| ▸ | UTS2R | Q9UKP6 | 9/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | RXRA | P19793 | 1/20 | 0.44 |
| ▸ | RXRB | P28702 | 1/20 | 0.44 |
| ▸ | RXRG | P48443 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20323088 | 0.85 | ALDH1A1 (0.55) | OPRK1SMN1; SMN2ALDH1A1L3MBTL1MAOA | |
| SCHEMBL15787095 | 0.83 | SMN1; SMN2 (0.46) | OPRK1UTS2RCYP3A4CYP2D6SMN1; SMN2 | |
| SCHEMBL28446159 | 0.80 | MMP14 (0.48) | OPRK1UTS2RCYP3A4CYP2D6SMN1; SMN2 | |
| SCHEMBL8541381 | 0.79 | ALDH1A1 (0.45) | UTS2RCYP3A4SMN1; SMN2ALDH1A1L3MBTL1 | |
| SCHEMBL2949925 | 0.79 | ALDH1A1 (0.45) | OPRK1UTS2RCYP3A4CYP2D6SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL19555432 | 0.78 | ALDH1A1 (0.44) | UTS2RCYP3A4SMN1; SMN2ALDH1A1L3MBTL1 | |
| SCHEMBL11008770 | 0.78 | RXRA (0.42) | OPRK1UTS2RCYP3A4CYP2D6SMN1; SMN2 | |
| SCHEMBL20322974 | 0.77 | HTR3E (0.47) | UTS2RALDH1A1L3MBTL1RXRARXRB | |
| SCHEMBL20322823 | 0.76 | SMN1; SMN2 (0.45) | UTS2RSMN1; SMN2ALDH1A1MAOAMAOB | |
| SCHEMBL19341421 | 0.76 | ALDH1A1 (0.56) | OPRK1UTS2RCYP3A4CYP2D6SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100256130-A1 | MORPHOLINYL AND PYRROLIDINYL ANALOGS | GOODMAN KRISTA B | 2010-10-07 | — | — | US | disclosed |
| US-20100256130-A1 | MORPHOLINYL AND PYRROLIDINYL ANALOGS | GOODMAN KRISTA B | 2010-10-07 | — | — | US | disclosed |
| US-20100256130-A1 | MORPHOLINYL AND PYRROLIDINYL ANALOGS | GOODMAN KRISTA B | 2010-10-07 | — | — | US | disclosed |
| US-7749998-B2 | Morpholinyl and pyrrolidinyl analogs | GLAXOSMITHKLINE LLC (US) | 2010-07-06 | — | — | US | disclosed |
| US-7749998-B2 | Morpholinyl and pyrrolidinyl analogs | GLAXOSMITHKLINE LLC (US) | 2010-07-06 | — | — | US | disclosed |
| US-7749998-B2 | Morpholinyl and pyrrolidinyl analogs | GLAXOSMITHKLINE LLC (US) | 2010-07-06 | — | — | US | disclosed |
| US-20090275571-A1 | MORPHOLINYL AND PYRROLIDINYL ANALOGS | SMITHKLINE BEECHAM CORPORATION | 2009-11-05 | — | — | US | disclosed |
| US-20090275571-A1 | MORPHOLINYL AND PYRROLIDINYL ANALOGS | SMITHKLINE BEECHAM CORPORATION | 2009-11-05 | — | — | US | disclosed |
| US-20090275571-A1 | MORPHOLINYL AND PYRROLIDINYL ANALOGS | SMITHKLINE BEECHAM CORPORATION | 2009-11-05 | — | — | US | disclosed |
| EP-2049118-A1 | MORPHOLINYL AND PYRROLIDINYL ANALOGS | SmithKline Beecham Corporation (US) | 2009-04-22 | — | — | EP | disclosed |
| US-7432258-B2 | Morpholinyl and pyrrolidinyl analogs | SMITHKLINE BEECHAM CORPORATION (US) | 2008-10-07 | — | — | US | disclosed |
| US-7432258-B2 | Morpholinyl and pyrrolidinyl analogs | SMITHKLINE BEECHAM CORPORATION (US) | 2008-10-07 | — | — | US | disclosed |
| US-7432258-B2 | Morpholinyl and pyrrolidinyl analogs | SMITHKLINE BEECHAM CORPORATION (US) | 2008-10-07 | — | — | US | disclosed |
| WO-2008011551-A1 | MORPHOLINYL AND PYRROLIDINYL ANALOGS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-01-24 | — | — | WO | disclosed |
| WO-2008011551-A1 | MORPHOLINYL AND PYRROLIDINYL ANALOGS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-01-24 | — | — | WO | disclosed |
| US-20080021023-A1 | 4'-[(1R)-1-[[(6,7-dichloro-3-oxo-2,3-dihydro-4H-1,4-benzoxazin- 4-yl)acetyl](methyl)amino]-2-(4-morpholinyl)ethyl]-4-biphenylcarboxylic acid; as antagonists of urotensin II, congestive heart failure, stroke, ischemic heart disease (e.g. angina, myocardial ischemia), cardiac arrhythmia, hypertension | GLAXOSMITHKLINE LLC | 2008-01-24 | — | — | US | disclosed |
| US-20080021023-A1 | 4'-[(1R)-1-[[(6,7-dichloro-3-oxo-2,3-dihydro-4H-1,4-benzoxazin- 4-yl)acetyl](methyl)amino]-2-(4-morpholinyl)ethyl]-4-biphenylcarboxylic acid; as antagonists of urotensin II, congestive heart failure, stroke, ischemic heart disease (e.g. angina, myocardial ischemia), cardiac arrhythmia, hypertension | GLAXOSMITHKLINE LLC | 2008-01-24 | — | — | US | disclosed |
| US-20080021023-A1 | 4'-[(1R)-1-[[(6,7-dichloro-3-oxo-2,3-dihydro-4H-1,4-benzoxazin- 4-yl)acetyl](methyl)amino]-2-(4-morpholinyl)ethyl]-4-biphenylcarboxylic acid; as antagonists of urotensin II, congestive heart failure, stroke, ischemic heart disease (e.g. angina, myocardial ischemia), cardiac arrhythmia, hypertension | GLAXOSMITHKLINE LLC | 2008-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256130-A1 | MORPHOLINYL AND PYRROLIDINYL ANALOGS | UTS2R, AVPR2, VIPR2 | OPRK1 207/4885UTS2R 1/4885CYP3A4 4049/4885 |
| US-20090275571-A1 | MORPHOLINYL AND PYRROLIDINYL ANALOGS | UTS2R, AVPR2, VIPR2 | OPRK1 207/4885UTS2R 1/4885CYP3A4 4049/4885 |
| US-20080021023-A1 | 4'-[(1R)-1-[[(6,7-dichloro-3-oxo-2,3-dihydro-4H-1,4-benzoxazin- 4-yl)acetyl](methyl)amino]-2-(4-morpholinyl)ethyl]-4-biphenylcarboxylic acid; as antagonists of urotensin II, congestive heart failure, stroke, ischemic heart disease (e.g. angina, myocardial ischemia), cardiac arrhythmia, hypertension | UTS2R, PLAUR, FABP3 | OPRK1 534/4885UTS2R 1/4885CYP3A4 2753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.